Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

Inclusion Criteria:

• Histological or pathological confirmation of pancreatic adenocarcinoma Cytologic orhistologic proof of pancreatic ductal adenocarcinoma (PDAC) needs to be verified bythe treating institution pathologist. A pathological report from non-treatinginstitutions is sufficient to consent and to initiate investigational therapy iftissue sample is unavailable for evaluation at time of consent or enrollment.However, in such a case, PDAC diagnosis should be confirmed by the treatinginstitution pathologist at a later time.

• Completed 8 cycles of neoadjuvant modified FOLFIRINOX. Omission of oxaliplatin dueto adverse events may be allowed in cycles 5-8 with consultation with the principalinvestigator.

• Patients with surgically resectable PDAC who are considered appropriate to undergothe applicable operation.

• Eligible to undergo SBRT.

• Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

• No prior surgical, systemic, or radiotherapy for PDAC except for mFOLFIRINOX.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Age ≥ 18 years.

• Adequate hematological and end-organ function, defined by the following laboratorytest results, obtained within 14 days prior to initiation of investigationaltreatment:

Exclusion Criteria:

• Prior treatment with T-cell co-stimulating or immune checkpoint blockade therapies,including but not limited to anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeuticantibodies.

• Patients who are receiving any other investigational agents concurrently.

• Concomitant treatment with other anti-neoplastic agents (hormonal therapyacceptable).

• Uncontrolled pleural effusion, pericardial effusion, or ascites.

• Uncontrolled hypercalcemia (ionized calcium > 1.5 mmol/L, calcium > 12 mg/dL, orcorrected serum calcium > ULN) or symptomatic hypercalcemia requiring continued useof bisphosphonate therapy.

• Active or history of autoimmune disease or immune deficiency, including, but notlimited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupuserythematosus, rheumatoid arthritis, inflammatory bowel disease (Crohn's disease orulcerative colitis), antiphospholipid antibody syndrome, Wegener granulomatosis,Sjögren's syndrome, Guillain-Barré syndrome, or multiple sclerosis (some exceptionspermissible as outlined per protocol).

• History of idiopathic pulmonary fibrosis, interstitial lung disease, organizingpneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathicpneumonitis, or evidence of active pneumonitis on screening chest CT scan.

• History of radiation pneumonitis in the radiation field (fibrosis) is permitted.

• Positive HIV test at screening or at any time prior to screening.

• Active hepatitis B virus (HBV) infection (chronic or acute), defined as having apositive hepatitis B surface antigen (HBsAg) test at screening.

--Note: Patients with a past or resolved HBV infection, defined as having a negativeHBsAg test and a positive total hepatitis B core antibody test at screening, areeligible for the study.

• Active hepatitis C virus (HCV) infection, defined as having a positive HCV antibodytest followed by a positive HCV RNA test at screening. The HCV RNA test will beperformed only for patients who have a positive HCV antibody test.

• Known clinically significant liver disease, including alcoholic hepatitis,cirrhosis, fatty liver disease, and inherited liver disease.

• Known active tuberculosis.

• Inability to swallow medication or malabsorption condition that would alter theabsorption of orally administered medications.

• Pregnant women are excluded from this study because there is an unknown butpotential risk for adverse events in nursing infants secondary to treatment of themother with these agents and breastfeeding should be discontinued.

• History of allergy or hypersensitivity to oxaliplatin, irinotecan, leucovorin,fluorouracil, pegfilgrastim, or any excipients.

• History of Gilbert's disease or known genotype UGT1A1 *28/*28.

• Inflammatory disease of the colon or rectum, or severe uncontrolled diarrhea.

• Active or history of celiac disease.

• Has known psychiatric or substance abuse disorders that would interfere withcooperation with the requirements of the trial.